4.44 USD
0.000.00%
盘后 4.74 +6.76%
2026-09-15
市值
$450.15M
市盈率
—
EPS
-0.85
股息率
—
52 周区间
1.45 – 8.00
成交量
2.00M
Beta
0.45
目标价
12.40
52W 低 1.4552W 高 8.00
价格走势
公司简介
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ...